Proposed RCT of fisetin on stem cell function and kidney outcomes in advanced chronic kidney disease
This is a proposed study protocol, not a completed trial. The researchers planned to examine whether fisetin would improve adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, inflammation markers, and physical function in individuals with advanced chronic kidney disease. No results are reported because the study has not been conducted.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jan 28, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- individuals with advanced chronic kidney disease
- Primary outcome
- adipose tissue-derived mesenchymal stem/stromal cell function
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Jan 28, 2026
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.